BND-22 | m-entrepreneurship.com

Product Name :
BND-22

Search keywords :
LILRB1

drugId :
null

Target Vo:
Leukocyte immunoglobulin-like receptor B1

Target Vo Short Name :
LILRB1

Moa_Name:
Leukocyte immunoglobulin-like receptor B1 inhibitors

First Approval Country :

First Approval Date Filter:
null

Origin Company_Name :
Biond Biologics Ltd

Active Company_Name :
Sanofi

Active Indication_Name:
Neoplasms

In Active Indication_Name:

Termination Status :

China Termination Status :

Highest Status:
Phase 2 Clinical

China Highest Status:

Antibodies are immunoglobulins secreted by effector lymphoid B cells into the bloodstream. Antibodies consist of two light peptide chains and two heavy peptide chains that are linked to each other by disulfide bonds to form a “Y” shaped structure. Both tips of the “Y” structure contain binding sites for a specific antigen. Antibodies are commonly used in medical research, pharmacological research, laboratory research, and health and epidemiological research. They play an important role in hot research areas such as targeted drug development, in vitro diagnostic assays, characterization of signaling pathways, detection of protein expression levels, and identification of candidate biomarkers.
Related websites: https://www.medchemexpress.com/antibodies.html
Popular product recommendations:
Lebrikizumab Autophagy
Brentuximab Epigenetic Reader Domain
Phospho-Chk2 (Thr68) Antibody: Phospho-Chk2 (Thr68) Antibody is a non-conjugated and Rabbit origined polyclonal antibody about 61 kDa, targeting to Phospho-Chk2 (Thr68). It can be used for WB,ICC/IF,IHC-P assays with tag free, in the background of Human, Mouse, Rat.

Author: Betaine hydrochloride

Related Posts